Avantax Advisory Services’s Alnylam Pharmaceuticals ALNY Stock Holding History

Avantax Advisory Services’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$472K	Buy	+1,446	New	+$400K	﹤0.01%	1616

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Avantax Advisory Services's ALNY Position: Q2 2025 in Review

Avantax Advisory Services opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2025: 1,446 shares worth $472K. The stake represents ﹤0.01% of the portfolio and ranks #1616 among its holdings.

653 funds tracked by Wall St. Rank hold ALNY as of Q2 2025.

Avantax Advisory Services held 1,446 shares of Alnylam Pharmaceuticals worth $472K as of Q2 2025.
Alnylam Pharmaceuticals was a new Avantax Advisory Services position in Q2 2025.
Alnylam Pharmaceuticals made up ﹤0.01% of Avantax Advisory Services's portfolio in Q2 2025, its #1616 holding.
653 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2025.

Based on Avantax Advisory Services's 13F filing for Q2 2025, filed 8 Aug 2025.